HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that data about the progress of Nymox’s drug development for NX-1207, the Company's investigational drug for benign prostatic hyperplasia (BPH), were presented this morning at the Annual Meeting of the North Central Section of the American Urological Association being held in Chicago. Neal D. Shore, MD, FACS, of Myrtle Beach, SC made the podium presentation. Dr. Shore is an independent clinical investigator who has participated in four of the NX-1207 clinical trials as well as six follow-up studies of the drug. Dr. Shore serves as an Editorial Consultant for Urology Times. NX-1207 is now in Phase 3 development.
